ThomasHGroteMD

PubMed

• 1 citations
  Secondary immune thrombocytopenia (ITP) as an initial presentation of Whipple’s disease
  David H. Priest, Thomas H. Grote, Sallie L. Staley, William S. Berger, Elizabeth S. Norman, Brian S. Smith> ;Idcases. 2017 Jun 28
• 3 citations
  Targeting Lymph Node Retrieval and Assessment in Stage II Colon Cancer: A Quality Outcome Community-Based Cancer Center Study
  Thomas H. Grote, Amy Herndon Hughes, Cathy C. Rimmer, Dale A. Less, Amy P. Abernethy> ;Journal of Oncology Practice. 2008 Mar 1
• 20 citations
  Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
  Julio Hajdenberg, Thomas Grote, Lorrin Yee, Roberto Arevalo-Araujo, Laurie A Latimer> ;The Journal of Supportive Oncology. 2006 Oct 1
• 56 citations
  Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant
  Thomas Grote, Julio Hajdenberg, Alan Cartmell, Susan Ferguson, Angela Ginkel, Veena Charu> ;The Journal of Supportive Oncology. 2006 Sep 1
• 64 citations
  Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade
  Manfred Blobner, Harald Groeben, Christopher Rex, Thomas Grote, Markus Neuhäuser, Martin Beiderlinden, Jürgen Peters> ;Anesthesia and Analgesia. 2006 Mar 1
• 65 citations
  Efficacy and Safety Analysis of Epoetin Alfa in Patients With Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
  Thomas Grote, Allen L. Yeilding, Rene Castillo, Dean Butler, Ellioth H. Fishkin, David H. Henry, Michael DeLeo, Kenneth Fink, Daniel J. Sullivan> ;Journal of Clinical Oncology. 2005 Dec 20
• Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy...
  Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Gallagher S, Charu V> ;J. Clin. Oncol.. 2004-07-15
• 266 citations
  Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
  Rudolph M. Navari, Rick R. Reinhardt, Richard J. Gralla, Mark G. Kris, Paul J. Hesketh, Ali Khojasteh, Hedy L. Kindler, Thomas H. Grote, Kelly Pendergrass, Steven M. G...> ;The New England Journal of Medicine. 1999 Jan 21
• 5 citations
  Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
  J. B. Whitmore, Mark G. Kris, Paul J. Hesketh, Thomas H. Grote, Dawn M. DuBois, Michael B. Cramer, William F. Hahne> ;Supportive Care in Cancer. 1998 Sep 1
• 15 citations
  Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
  Mark G. Kris, Kelly Pendergrass, Rudolph M. Navari, Thomas H. Grote, A M Nelson, V Thomas, B B Ferguson, D S Allman, Barbara Pizzo, T W Baker, I J Fernando, S B Chernoff> ;Journal of Clinical Oncology. 1997 May 1
• 30 citations
  Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy†
  Edward B. Rubenstein, Richard J. Gralla, John D. Hainsworth, Paul J. Hesketh, Thomas H. Grote, Manuel Modiano, Ali Khojasteh, L A Kalman, Claude R. Benedict, William F...> ;Cancer. 1997 Mar 15
• 18 citations
  Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
  Thomas H. Grote, Pineda Lf, Figlin Ra, Kelly Pendergrass, Paul J. Hesketh, Karlan By, Reeves Ja, Porter Ll, Claude R. Benedict, William F. Hahne> ;The Cancer Journal from Scientific American. 1997 Jan 1
• 98 citations
  Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-indu...
  Paul J. Hesketh, Rudolph M. Navari, T Grote, Richard J. Gralla, J Hainsworth, Mark G. Kris, L Anthony, Ali Khojasteh, E Tapazoglou, C Benedict, W Hahne> ;Journal of Clinical Oncology. 1996 Aug 1
• 9 citations
  Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association.
  James N. Atkins, Hyman B. Muss, L. Douglas Case, Frederick Richards, Thomas Grote, James McFarland> ;American Journal of Clinical Oncology. 1996 Feb 1
• 14 citations
  Primary lymphoma of the central nervous system. A report of 20 cases and a review of the literature.
  Thomas H. Grote, W W Grosh, Alan F. List, Ron Wiley, John B. Cousar, David H. Johnson> ;American Journal of Clinical Oncology. 1989 Apr 1
• 61 citations
  Atypical carcinoid of the lung. A distinct clinicopathologic entity.
  T. H. Grote, W. R. Macon, B. W. Davis, F A Greco, David H. Johnson> ;Chest. 1988 Feb 1
• 17 citations
  Hypercalcemia and Elevated Serum Calcitriol in a Patient With Seminoma
  Thomas H. Grote, John D. Hainsworth> ;Archives of Internal Medicine. 1987 Dec 1
• 17 citations
  High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.
  James N. Atkins, Hyman B. Muss, Douglas Case, J. Brockschmidt, Frederick M. Schnell, M A O'Rourke, T. H. Grote, J. H. West, S. Anthony, V. Stanley> ;American Journal of Clinical Oncology. 1991 Dec 1
• Join now to see all